Kasparek Petr, Ileninova Zuzana, Zbodakova Olga, Kanchev Ivan, Benada Oldrich, Chalupsky Karel, Brattsand Maria, Beck Inken M, Sedlacek Radislav
Laboratory of Transgenic Models of Diseases, Division BIOCEV, Institute of Molecular Genetics of the Czech Academy of Sciences, v.v.i., Vestec, Czech Republic.
Faculty of Sciences, Charles University in Prague, Prague, Czech Republic.
PLoS Genet. 2017 Jan 17;13(1):e1006566. doi: 10.1371/journal.pgen.1006566. eCollection 2017 Jan.
Netherton syndrome (NS) is a severe skin disease caused by the loss of protease inhibitor LEKTI, which leads to the dysregulation of epidermal proteases and severe skin-barrier defects. KLK5 was proposed as a major protease in NS pathology, however its inactivation is not sufficient to rescue the lethal phenotype of LEKTI-deficient mice. In this study, we further elucidated the in vivo roles of the epidermal proteases in NS using a set of mouse models individually or simultaneously deficient for KLK5 and KLK7 on the genetic background of a novel NS-mouse model. We show that although the ablation of KLK5 or KLK7 is not sufficient to rescue the lethal effect of LEKTI-deficiency simultaneous deficiency of both KLKs completely rescues the epidermal barrier and the postnatal lethality allowing mice to reach adulthood with fully functional skin and normal hair growth. We report that not only KLK5 but also KLK7 plays an important role in the inflammation and defective differentiation in NS and KLK7 activity is not solely dependent on activation by KLK5. Altogether, these findings show that unregulated activities of KLK5 and KLK7 are responsible for NS development and both proteases should become targets for NS therapy.
Netherton综合征(NS)是一种由蛋白酶抑制剂LEKTI缺失引起的严重皮肤病,这会导致表皮蛋白酶失调和严重的皮肤屏障缺陷。KLK5被认为是NS病理中的主要蛋白酶,然而其失活不足以挽救LEKTI缺陷小鼠的致死表型。在本研究中,我们使用一组在新型NS小鼠模型的遗传背景上单独或同时缺乏KLK5和KLK7的小鼠模型,进一步阐明了表皮蛋白酶在NS中的体内作用。我们发现,虽然敲除KLK5或KLK7不足以挽救LEKTI缺陷的致死效应,但同时缺乏这两种激肽释放酶可完全挽救表皮屏障和出生后致死性,使小鼠成年后皮肤功能完全正常且毛发生长正常。我们报告称,不仅KLK5,而且KLK7在NS的炎症和分化缺陷中也起重要作用,并且KLK7的活性并不完全依赖于KLK5的激活。总之,这些发现表明,KLK5和KLK7的不受调控的活性是NS发展的原因,这两种蛋白酶都应成为NS治疗的靶点。